Cargando…

Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: A Review Article

Sphingosine-1-phosphate (S1P), via its G-protein-coupled receptors, is a signaling molecule with important regulatory properties on numerous, widely varied cell types. Five S1P receptors (S1PR1-5) have been identified, each with effects determined by their unique G-protein-driven downstream pathways...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohan, Stanley, Lucassen, Elisabeth, Smoot, Kyle, Brink, Justine, Chen, Chiayi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400006/ https://www.ncbi.nlm.nih.gov/pubmed/32708516 http://dx.doi.org/10.3390/biomedicines8070227

Ejemplares similares

Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study
por: Smoot, Kyle, et al.
Publicado: (2021)

The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide
por: Cohan, Stanley, et al.
Publicado: (2021)

Advancing Care and Outcomes for African American Patients With Multiple Sclerosis
por: Okai, Annette F., et al.
Publicado: (2022)

MRI utility in the detection of disease activity in clinically stable patients with multiple sclerosis: a retrospective analysis of a community based cohort
por: Cohan, Stanley, et al.
Publicado: (2016)

Results of sustained long-term use of interferon beta-1a in a community-based cohort of patients with relapsing multiple sclerosis
por: Cohan, Stanley, et al.
Publicado: (2015)

Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy
por: Cohan, Stanley L, et al.
Publicado: (2019)

Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis
por: Cohan, Stanley L., et al.
Publicado: (2019)

Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry
por: Stuchiner, Tamela, et al.
Publicado: (2020)

Sphingosine 1-Phosphate Receptor 1 as a Useful Target for Treatment of Multiple Sclerosis
por: Chiba, Kenji, et al.
Publicado: (2012)

Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis
por: Pérez-Jeldres, Tamara, et al.
Publicado: (2021)

An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis
por: Dumitrescu, Laura, et al.
Publicado: (2023)

Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis
por: Musella, Alessandra, et al.
Publicado: (2020)

Correction to: Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis
por: Pérez-Jeldres, Tamara, et al.
Publicado: (2021)

Sphingosine 1-Phosphate Signaling and Its Pharmacological Modulation in Allogeneic Hematopoietic Stem Cell Transplantation
por: Smith, Philip, et al.
Publicado: (2017)

Outcomes of Stable Multiple Sclerosis Patients Staying on Initial Interferon Beta Therapy Versus Switching to Another Interferon Beta Therapy: A US Claims Database Study
por: Cohan, Stanley, et al.
Publicado: (2018)

Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)
por: Cohan, Stanley L., et al.
Publicado: (2021)

Interaction of microRNAs with sphingosine kinases, sphingosine-1 phosphate, and sphingosine-1 phosphate receptors in cancer
por: Xu, Guangmeng, et al.
Publicado: (2021)

COVID-19 in MS: Initial observations from the Pacific Northwest
por: Bowen, James D., et al.
Publicado: (2020)

Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis
por: Comi, Giancarlo, et al.
Publicado: (2017)

The Role of Sphingolipids and Sphingosine-1-phosphate—Sphingosine-1-phosphate-receptor Signaling in Psoriasis
por: Masuda-Kuroki, Kana, et al.
Publicado: (2023)

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
por: Cohan, Stanley
Publicado: (2016)

Autoimmunity to Sphingosine-1-Phosphate-Receptors in Systemic Sclerosis and Pulmonary Arterial Hypertension
por: Gluschke, Hans, et al.
Publicado: (2022)

Regulation of Immune Cell Migration by Sphingosine-1-Phosphate
por: Kumar, A., et al.
Publicado: (2015)

Sphingosine 1-Phosphate and Atherosclerosis
por: Kurano, Makoto, et al.
Publicado: (2018)

Selectivity and Specificity of Sphingosine 1-Phosphate Receptor Ligands: “Off-Targets” or Complex Pharmacology?
por: Pyne, Nigel J., et al.
Publicado: (2011)

Potential of a sphingosine 1-phosphate receptor antagonist and sphingosine kinase inhibitors as targets for multiple myeloma treatment
por: Tanaka, Yuko, et al.
Publicado: (2022)

The role of sphingosine 1‐phosphate and its receptors in cardiovascular diseases
por: Ouyang, Jie, et al.
Publicado: (2020)

Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects
por: Chun, Jerold, et al.
Publicado: (2020)

Sphingosine Kinase 1 and Sphingosine-1-Phosphate Signaling in Colorectal Cancer
por: Bao, Yonghua, et al.
Publicado: (2017)

Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer
por: Matula, Kasia, et al.
Publicado: (2015)

Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer’s disease
por: Ceccom, Johnatan, et al.
Publicado: (2014)

Elevated Serum Levels of Arachidonoyl-lysophosphatidic Acid and Sphingosine 1-Phosphate in Systemic Sclerosis
por: Tokumura, Akira, et al.
Publicado: (2009)

Sphingosine-1-phosphate phosphohydrolase in regulation of sphingolipid metabolism and apoptosis
por: Le Stunff, Hervé, et al.
Publicado: (2002)

The signaling lipid sphingosine 1-phosphate regulates mechanical pain
por: Hill, Rose Z, et al.
Publicado: (2018)

Is Sphingosine-1-Phosphate a Regulator of Tumor Vascular Functionality?
por: Karam, Manale, et al.
Publicado: (2022)

Dihydro-sphingosine 1-phosphate interacts with carrier proteins in a manner distinct from that of sphingosine 1-phosphate
por: Mishima, Yuko, et al.
Publicado: (2018)

Irisin Is Target of Sphingosine-1-Phosphate/Sphingosine-1-Phosphate Receptor-Mediated Signaling in Skeletal Muscle Cells
por: Pierucci, Federica, et al.
Publicado: (2023)

Sphingosine kinase and sphingosine-1-phosphate regulate epithelial cell architecture by the modulation of de novo sphingolipid synthesis
por: Santacreu, Bruno Jaime, et al.
Publicado: (2019)

Sphingosine Kinases/Sphingosine-1-Phosphate and Death Signalling in APP-Transfected Cells
por: Gassowska, Magdalena, et al.
Publicado: (2014)

Characterizing Sphingosine Kinases and Sphingosine 1-Phosphate Receptors in the Mammalian Eye and Retina
por: Porter, Hunter, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hkrvql2ko9bh8u5rgeuhq5h21l